Scorpius Holdings(SCPX) - 2024 Q2 - Quarterly Results

Form 8-K Current Report Item 2.02. Results of Operations and Financial Condition Scorpius Holdings, Inc. announced preliminary unaudited Q2 2024 financial results, projecting revenue between $0.3 million and $0.8 million and an operating loss of $8.6 million to $9.1 million, with larger cGMP manufacturing contracts expected to contribute to revenue starting Q3 2024 Preliminary Unaudited Financial Estimates for Q2 2024 | Financial Metric | Estimated Range (in millions) | | :--- | :--- | | Revenue | $0.3 - $0.8 | | Operating Loss | $8.6 - $9.1 | | Net Loss Before Income Taxes (from continuing operations) | $9.2 - $9.7 | - As of June 30, 2024, the company's cash, cash equivalents, and short-term investments were approximately $1.5 million[3] - Revenue for the first six months of 2024 was primarily from process development work, with anticipated revenue generation from microbial cGMP manufacturing, which began in July 2024, and mammalian cGMP manufacturing, expected to start in Q3 2024, with these manufacturing contracts projected to be larger than current process development contracts[3] - The provided financial estimates are preliminary, based on currently available information, and are subject to adjustments upon completion of the company's financial closing procedures, and have not been audited or reviewed by the company's independent registered public accounting firm[4] Item 9.01 Financial Statements and Exhibits This section details the exhibits filed as part of the Form 8-K report - Exhibit 104, the Cover Page Interactive Data File, was filed with this report[2][5]